Stereotactic biopsy complications
The most frequent complication after stereotactic biopsy is hemorrhage, although most are too small to have a clinical impact. The risk of a major complication (mostly due to hemorrhage) in nonimmunocompromised (NIC) patients ranges from 0–3% (with most < 1%), and 0–12% in AIDS 1)
Higher complication rates seen in AIDS patients in some series may be due to reduced platelet count or function, and to vessel fragility in primary CNS lymphoma. In NIC patients, multifocal high-grade gliomas had the highest complication rate. Infection is an infrequent complication with a needle biopsy.
About 132 articles were found after research in the Medline database. Riche et al. only considered English references published between 1994 and June 2019. Additional studies were found by using the references from articles identified in the original search. This systematic review was conducted according to PRISMA guidelines. After applying exclusion criteria, they eventually considered 25 relevant studies. The mortality rate varies from 0.7 to 4%. Overall morbidity ranges from 3 to 13%. Most of the complications are revealed by the following symptoms: neurological impairment (transient or permanent), seizure, and unconsciousness. Symptomatic hemorrhage range varies from 0.9 to 8.6%, whereas considering asymptomatic bleeding, the range may be up to 59.8%. Complications were clinically evident within minutes to a few hours after the biopsy. Corrective surgeries are very rare (< 1%). Complications occurring after a frame-based stereotactic brain biopsy are rare but with serious side effects. It rarely leads to death or to permanent neurological impairment. The description and classification of complications are often heterogeneous in the literature. The use of a grading scale could help comparisons between series from around the world. Future studies should establish a score that allows neurosurgeon to predict post-biopsy complications 2).
Livermore et al., advocate intra-operative histopathological analysis to decrease negative biopsy rates and advise increased caution when undertaking biopsies of deep lesions or suspected lymphoma cases due to the potentially increased risk of hemorrhage 8).